Literature DB >> 26700673

miR-497 inhibits epithelial mesenchymal transition in breast carcinoma by targeting Slug.

Zhihao Wu1, Xiangli Li1, Xuehong Cai2, Chenggang Huang2, Min Zheng3,4.   

Abstract

Epithelial to mesenchymal transition (EMT) is a critical step in the growth and dissemination of malignant diseases, including breast cancer. It is known that microRNAs (miRNAs) play important roles in the regulation of tumor properties in cancers. However, whether miR-497 contributes to EMT in breast cancer cells remains unknown. Our study demonstrated that the expression of miR-497 was significantly decreased in human breast cancer cell lines and breast cancer specimens. In breast cancer cells, EMT was inhibited and promoted by the over-expression as well as depletion of miR-497, respectively. Dual-Luciferase ReporterAassay confirmed that Slug was a direct target of miR-497. The upregulation of miR-497 in breast cancer cells suppressed cell proliferation and induced apoptosis both in vitro and in vivo. Correlation analysis indicated that miR-497 was highly negatively correlated with Slug expression in breast cancer specimens. The knockdown of Slug expression in breast cancer cells significantly suppressed cell proliferation and promoted apoptosis. Our results suggested that the expression of miR-497 is significantly correlated with EMT in breast cancer cells by regulating Slug at the transcriptional as well as translational levels. Therefore, targeting miR-497 may provide a novel strategy for the treatment of breast cancer.

Entities:  

Keywords:  Apoptosis; Breast cancer; EMT; Slug; miR-497

Mesh:

Substances:

Year:  2015        PMID: 26700673     DOI: 10.1007/s13277-015-4665-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

1.  MiR-497 Suppresses YAP1 and Inhibits Tumor Growth in Non-Small Cell Lung Cancer.

Authors:  Chongbiao Huang; Ruijue Ma; Jie Yue; Na Li; Zengxun Li; Daliang Qi
Journal:  Cell Physiol Biochem       Date:  2015-08-24

2.  MiR-23b and miR-199a impair epithelial-to-mesenchymal transition during atrioventricular endocardial cushion formation.

Authors:  Fernando Bonet; Ángel Dueñas; Carmen López-Sánchez; Virginio García-Martínez; Amelia E Aránega; Diego Franco
Journal:  Dev Dyn       Date:  2015-08-26       Impact factor: 3.780

3.  MicroRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer.

Authors:  Chuankui Wei; Qifeng Luo; Xiaoguo Sun; Dengfeng Li; Hongming Song; Xiaoyu Li; Jialu Song; Kaiyao Hua; Lin Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

4.  Down-regulation of miR-129-5p via the Twist1-Snail feedback loop stimulates the epithelial-mesenchymal transition and is associated with poor prognosis in breast cancer.

Authors:  Yue Yu; Ying Zhao; Xiao-Hu Sun; Jie Ge; Bin Zhang; Xin Wang; Xu-Chen Cao
Journal:  Oncotarget       Date:  2015-10-27

5.  MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.

Authors:  Shaohua Xu; Guang-Bo Fu; Zhen Tao; Jun OuYang; Fanfei Kong; Bing-Hua Jiang; Xiaoping Wan; Ke Chen
Journal:  Oncotarget       Date:  2015-09-22

6.  Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma.

Authors:  Min Zheng; Ya-ping Jiang; Wei Chen; Kai-de Li; Xin Liu; Shi-yu Gao; Hao Feng; Sha-sha Wang; Jian Jiang; Xiang-rui Ma; Xiao Cen; Ya-jie Tang; Yu Chen; Yun-feng Lin; Ya-ling Tang; Xin-hua Liang
Journal:  Oncotarget       Date:  2015-03-30

7.  Down-Regulation of NDUFB9 Promotes Breast Cancer Cell Proliferation, Metastasis by Mediating Mitochondrial Metabolism.

Authors:  Liang-Dong Li; He-Fen Sun; Xue-Xiao Liu; Shui-Ping Gao; Hong-Lin Jiang; Xin Hu; Wei Jin
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

8.  Resveratrol inhibits epithelial-mesenchymal transition of retinal pigment epithelium and development of proliferative vitreoretinopathy.

Authors:  Keijiro Ishikawa; Shikun He; Hiroto Terasaki; Hossein Nazari; Huiming Zhang; Christine Spee; Ram Kannan; David R Hinton
Journal:  Sci Rep       Date:  2015-11-10       Impact factor: 4.379

9.  Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach.

Authors:  Julia Beretov; Valerie C Wasinger; Ewan K A Millar; Peter Schwartz; Peter H Graham; Yong Li
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

10.  Hsa-miR-19a is associated with lymph metastasis and mediates the TNF-α induced epithelial-to-mesenchymal transition in colorectal cancer.

Authors:  Lanlan Huang; Xiaoyan Wang; Chuangyu Wen; Xiangling Yang; Minmin Song; Junxiong Chen; Chenliang Wang; Bo Zhang; Lei Wang; Aikichi Iwamoto; Jianping Wang; Huanliang Liu
Journal:  Sci Rep       Date:  2015-08-25       Impact factor: 4.379

View more
  14 in total

Review 1.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

2.  Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes.

Authors:  A Mizrahi; A Barzilai; D Gur-Wahnon; I Z Ben-Dov; S Glassberg; T Meningher; E Elharar; M Masalha; J Jacob-Hirsch; H Tabibian-Keissar; I Barshack; J Roszik; R Leibowitz-Amit; Y Sidi; D Avni
Journal:  Oncogene       Date:  2017-09-18       Impact factor: 9.867

Review 3.  Review article epithelial to mesenchymal transition‑associated microRNAs in breast cancer.

Authors:  Hossein Javdani; Homa Mollaei; Farzaneh Karimi; Shiva Mahmoudi; Ali Farahi; Mohamad Javad Mirzaei-Parsa; Arman Shahabi
Journal:  Mol Biol Rep       Date:  2022-06-18       Impact factor: 2.742

4.  MicroRNA-497 downregulation contributes to cell proliferation, migration, and invasion of estrogen receptor alpha negative breast cancer by targeting estrogen-related receptor alpha.

Authors:  Li Han; Bo Liu; Lixi Jiang; Junyan Liu; Shumei Han
Journal:  Tumour Biol       Date:  2016-07-25

5.  MicroRNA signature in the chemoprevention of functionally-enriched stem and progenitor pools (FESPP) by Active Hexose Correlated Compound (AHCC).

Authors:  Émilie A Graham; Jean-François Mallet; Majed Jambi; Hiroshi Nishioka; Kohei Homma; Chantal Matar
Journal:  Cancer Biol Ther       Date:  2017-09-08       Impact factor: 4.742

6.  MiR-646 inhibited cell proliferation and EMT-induced metastasis by targeting FOXK1 in gastric cancer.

Authors:  P Zhang; W M Tang; H Zhang; Y Q Li; Y Peng; J Wang; G N Liu; X T Huang; J J Zhao; G Li; A M Li; Y Bai; Y Chen; Y X Ren; G X Li; Y D Wang; S D Liu; J D Wang
Journal:  Br J Cancer       Date:  2017-06-20       Impact factor: 7.640

7.  MicroRNA‑497 inhibits cellular proliferation, migration and invasion of papillary thyroid cancer by directly targeting AKT3.

Authors:  Juhua Zhuang; Ying Ye; Guoyu Wang; Jing Ni; Saifei He; Cuihua Hu; Wei Xia; Zhongwei Lv
Journal:  Mol Med Rep       Date:  2017-08-24       Impact factor: 3.423

8.  Oncogenic long noncoding RNA landscape in breast cancer.

Authors:  Shouping Xu; Dejia Kong; Qianlin Chen; Yanyan Ping; Da Pang
Journal:  Mol Cancer       Date:  2017-07-24       Impact factor: 27.401

9.  Identification of novel biomarkers to monitor β-cell function and enable early detection of type 2 diabetes risk.

Authors:  Kirstine J Belongie; Ele Ferrannini; Kjell Johnson; Patricia Andrade-Gordon; Michael K Hansen; John R Petrie
Journal:  PLoS One       Date:  2017-08-28       Impact factor: 3.240

10.  Identification of micro-RNA expression profile related to recurrence in women with ESMO low-risk endometrial cancer.

Authors:  Tiphaine de Foucher; Maria Sbeih; Jenifer Uzan; Sofiane Bendifallah; Marine Lefevre; Nathalie Chabbert-Buffet; Selim Aractingi; Catherine Uzan; Issam Abd Alsalam; Rana Mitri; Romain H Fontaine; Emile Daraï; Bassam Haddad; Céline Méhats; Marcos Ballester; Geoffroy Canlorbe; Cyril Touboul
Journal:  J Transl Med       Date:  2018-05-21       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.